The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome

Phase 4

Second Affiliated Hospital, School of Medicine, Zhejiang University

Hydroxychloroquine